Rebecca Blanchard, Ph.D.

Rebecca Blanchard is the head of Clinical Pharmacogenomics within the Human Genetics and Pharmacogenomics department at Merck & Co., Inc.  Dr. Blanchard’s career in academia and at Merck has spanned preclinical, translational, and clinical development across multiple therapeutic areas.  Rebecca’s education includes a B.S. in Pharmacy from Albany College of Pharmacy and a Ph.D. in Pharmaceutical Chemistry from the University of Utah in Salt Lake City, Utah.  After receiving her Ph.D., Rebecca completed postdoctoral studies at the Mayo Clinic with a focus on human pharmacogenetics.  From 1998 through 2004 Rebecca was an Assistant Professor at Fox Chase Cancer Center in Philadelphia where she continued to investigate human pharmacogenetics with emphasis on human sulfotransferase and UDP-glucuronosyltransferase genes.  Her research at Fox Chase also focused on pharmacogenomics as related to anticancer therapies.  In 2004, Rebecca joined Merck & Co., Inc. in Pennsylvania. She has held positions of increasing responsibility across several departments within the organization since her arrival.  Rebecca has led several Drug Development teams across early and late stage development, with a recent focus on identification of predictive biomarkers for drug response.  In 2013 Rebecca accepted the position of Head of Clinical Pharmacogenomics, where she is responsible for the scientific strategy and execution of Merck’s Clinical Pharmacogenomic efforts.